Acrivon Therapeutics, Inc. ACRV

Institutional shares held 22.4 Million

0 calls

0 puts

Total value of holdings $0

$0 calls

$0 puts

Market Cap N/A

Institutional ownership N/A

# of Institutions 59

We take great care to ensure that the data presented and summarized in this overview for Acrivon Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.

Quarterly Institutional Activity in ACRV

Shares Bought

Shares Sold

View Transactions

Top Institutions Holding ACRV

View all

Latest Institutional Activity in ACRV

Top Purchases

Q1 2025

Gamma Investing LLC Shares Held: 583 ($0)

549 Shares purchased

1614.71% Added

Q4 2024

Acorn Capital Advisors, LLC Shares Held: 405K ($0)

405K Shares purchased

New Holding

Q4 2024

Goldman Sachs Group Inc Shares Held: 238K ($0)

39.4K Shares purchased

19.87% Added

Q4 2024

Vanguard Group Inc Shares Held: 672K ($0)

34.1K Shares purchased

5.35% Added

Q4 2024

Ubs Oconnor LLC Shares Held: 103K ($0)

23.5K Shares purchased

29.7% Added

View All Buyers

Top Sells

Q1 2025

Rhumbline Advisers Shares Held: 16.6K ($0)

1.16K Shares sold

6.51% Reduced

Q4 2024

Marshall Wace, LLP Shares Held: 598K ($0)

212K Shares sold

26.19% Reduced

Q4 2024

Citadel Advisors LLC Shares Held: 2.12M ($0)

21K Shares sold

0.98% Reduced

Q4 2024

Trexquant Investment LP Shares Held: 16.9K ($0)

13.5K Shares sold

44.47% Reduced

Q4 2024

Nuveen Asset Management, LLC Shares Held: 13.4K ($0)

12.4K Shares sold

48.01% Reduced

View All Sellers

About ACRV

Insider Transactions at ACRV

Insider Transaction List

View all

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Feb 21 2025	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Direct	19,904 -0.86%	$99,520 $5.54 P/Share
Feb 14 2025	Katharine Peterson Chief Accounting Officer	SELL Payment of exercise price or tax liability	Direct	116 -2.56%	$580 $5.42 P/Share
Feb 14 2025	Rasmus Holm Jorgensen Chief Financial Officer	SELL Payment of exercise price or tax liability	Direct	434 -1.64%	$2,170 $5.42 P/Share
Feb 14 2025	Mary Miller Chief Legal Officer	SELL Payment of exercise price or tax liability	Direct	217 -0.58%	$1,085 $5.42 P/Share
Feb 14 2025	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Indirect	579 -0.18%	$2,895 $5.42 P/Share
Feb 14 2025	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Direct	37,152 -1.59%	$185,760 $5.42 P/Share
Feb 14 2025	Eric Devroe Chief Operating Officer	SELL Payment of exercise price or tax liability	Direct	724 -1.07%	$3,620 $5.42 P/Share
Feb 14 2025	Erick Gamelin Chief Development Officer	SELL Payment of exercise price or tax liability	Direct	469 -2.77%	$2,345 $5.42 P/Share
Jan 17 2025	Mary Miller Chief Legal Officer	SELL Payment of exercise price or tax liability	Direct	659 -1.74%	$3,295 $5.78 P/Share
Nov 21 2024	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Direct	19,910 -0.84%	$119,460 $6.44 P/Share
Nov 14 2024	Erick Gamelin Chief Development Officer	SELL Payment of exercise price or tax liability	Direct	402 -2.32%	$2,814 $7.92 P/Share
Nov 14 2024	Rasmus Holm Jorgensen Chief Financial Officer	SELL Payment of exercise price or tax liability	Direct	368 -1.37%	$2,576 $7.92 P/Share
Nov 14 2024	Mary Miller Chief Legal Officer	SELL Payment of exercise price or tax liability	Direct	184 -0.48%	$1,288 $7.92 P/Share
Nov 14 2024	Katharine Peterson Chief Accounting Officer	SELL Payment of exercise price or tax liability	Direct	99 -2.14%	$693 $7.92 P/Share
Nov 14 2024	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Indirect	490 -0.15%	$3,430 $7.92 P/Share
Nov 14 2024	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Direct	59,766 -2.47%	$418,362 $7.92 P/Share
Nov 14 2024	Eric Devroe Chief Operating Officer	SELL Payment of exercise price or tax liability	Direct	613 -0.9%	$4,291 $7.92 P/Share
Oct 17 2024	Mary Miller Chief Legal Officer	SELL Payment of exercise price or tax liability	Direct	558 -1.44%	$3,906 $7.87 P/Share
Oct 01 2024	Mary Miller Chief Legal Officer	SELL Payment of exercise price or tax liability	Direct	284 -0.73%	$1,704 $6.98 P/Share
Aug 21 2024	Peter Blume Jensen President and CEO	SELL Payment of exercise price or tax liability	Direct	79,616 -3.18%	$716,544 $9.19 P/Share

View All Transactions

Last 12 Months Summary

Buy / Acquisition

5.89M Shares

From 3 Insiders

Open market or private purchase	2.35M shares
Grant, award, or other acquisition	3.53M shares
Exercise of conversion of derivative security	10K shares

Sell / Disposition

343K Shares

From 7 Insiders

Payment of exercise price or tax liability	343K shares

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRV shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Acrivon Therapeutics, Inc. insider buys or sells ACRV shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to Acrivon Therapeutics, Inc.

Track Activities on ACRV

Account

Acrivon Therapeutics, Inc. ACRV

Quarterly Institutional Activity in ACRV

Top Institutions Holding ACRV

Latest Institutional Activity in ACRV

Top Purchases

Top Sells

About ACRV

Insider Transactions at ACRV

Insider Transaction List

Last 12 Months Summary

Track Institutional and Insider Activities on ACRV

Institutional Portfolio Updates

Insider Trading

News